Over the past few years, the WEB-RADR (Recognising Adverse Drug Reactions) project, part of the European Union’s Innovative Medicines Initiative, has investigated the role and usefulness of social media in pharmacovigilance, evaluating the strengths and weaknesses of this emerging data source, the effectiveness of existing analytical algorithms, and potential areas for improvement.
At the conclusion of the project, experts developed a series of recommendations to help guide the future use of social media in pharmacovigilance.
Which social media platforms should be used?
Although previous studies have suggested that data from social media may be more informative than spontaneous adverse drug reaction (ADR) reporting, the WEB-RADR researchers concluded that the value of social media platforms should be assessed on a case-by-case basis, according to the relative richness of information on medicinal products and safety issues compared with the overall volume of available data.
Common social media platforms such as Facebook and Twitter appear to be of limited value for identifying new pharmacovigilance signals. Despite generating large amounts of data, the quality and informational value of individual posts tend to be relatively low.
In addition, the predictive ability of these networks—that is, their capacity to identify emerging safety concerns early or reveal new aspects of already known issues—has proven to be very limited. Consequently, they are often resource-intensive while providing limited benefits in the context of signal detection.
For the identification of new safety signals, the authors recommend using more specialized social media platforms and prospectively identifying those best suited for specific objectives, based on the absolute and relative number of posts concerning particular medicines or events of interest.
Examples of platforms considered more useful for signal detection include Patient Forums, which offer dedicated sections for specific diseases, medicines, or patient populations, and Reddit, whose “subreddits” provide discussion forums focused on highly specific topics.
Where should future research focus?
Despite their limited usefulness for identifying ADRs, social media platforms may be particularly valuable for redefining or reassessing already known adverse reactions, especially regarding their impact on quality of life.
According to WEB-RADR, 12% of the analyzed posts contained information related to quality-of-life issues—such as sleep disturbances, anxiety, depression, and similar conditions—which can be extremely valuable, particularly in the neuropsychiatric field.
Another promising area involves specialized or niche topics, such as medicine use during pregnancy and cases of drug misuse or abuse, where combining traditional pharmacovigilance methods with social media data may genuinely improve signal detection.
Future research should therefore focus on improving predictive algorithms in order to enhance signal identification capabilities, reduce duplication and ambiguity, increase efficiency, and, where possible, lower the costs associated with these technologies.
Toward a more comprehensive and coordinated pharmacovigilance system
The use of social media is part of a broader transformation of pharmacovigilance, which is evolving from the simple identification and description of adverse events to a more holistic evaluation of a medicine’s overall benefit-risk profile.
Going forward, it will be necessary to better define the strengths and limitations of the internet as a source of safety information, coordinate and maximize research efforts, and above all create a collaborative environment involving multiple stakeholders.
Such collaboration is essential for advancing this field of research and supporting the development and adoption of new approaches to pharmacovigilance.
SOURCE